QTTB · Q32 Bio Inc.
Price
Snapshot
50 fields · last close| Market Cap | $267.0M |
| P/E | 8.88 |
| Float | 22.43M |
| Beta | 0.59 |
| Volatility 30D | 70.7% |
| Exchange | NASDAQ |
| Sector | Biotechnology |
| Cap tier | Micro cap |
| Macro sensitivity | Low |
| Clavix score | 35.3 |
| Price | 8.56 |
| Change | −4.57% |
| Prev Close | 8.97 |
| Open | 8.87 |
| Day Low | 8.51 |
| Day High | 9.17 |
| Avg Vol | 0 |
| Avg $ Vol | $3.38M |
| 52W High | 23.57 |
| 52W Low | 1.91 |
| 52W Pos | 30.7% |
| From High | −63.68% |
| From Low | +349.34% |
| Max DD 1Y | −64.83% |
| Spread | 0.10% |
| Liquidity | Thin |
| SMA 20 | +1.00% |
| SMA 50 | −14.43% |
| SMA 200 | −8.08% |
| RSI (14) | 49.6 |
| Vol 90D | 133.1% |
| Vol 1Y | 140.4% |
| 1Y Range | 2–24 |
| Daily bars | 549 |
| Perf Week | −0.99% |
| Perf Month | +10.60% |
| Perf Quarter | −44.63% |
| Perf Half Y | +63.99% |
| Perf Year | +249.03% |
| Perf YTD | +148.84% |
| Prev Day | −4.57% |
| Clavix | F |
| Debt / Eq | 2.29 |
| Curr Ratio | 4.85 |
| Int Cover | — |
| FCF Margin | −62.4% |
| Rev Growth | +155.8% |
| Profit | Profitable |
| Leverage | High |
| Sector rank | 32 / 35 |
Clavix risk grade
regraded every trading dayQTTB grades F, 35.3 of 100. Steadiest on News Sentiment (68), most exposed on Price Stability (12, weak). 1 of the 4 weighted dimensions sit above the Biotechnology median. Ranks 32 of 35 in Biotechnology by Clavix score.
How rough the ride is
| QTTB | Biotechnology median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.59 | 0.49 |
| 30-day realized volatilityannualized, from daily closes | 70.7% | 46.0% |
| Max drawdown, past yearworst peak-to-trough fall | −64.8% | — |
| Typical daily movemedian absolute daily change | 3.54% | — |
| Days beyond ±3%of the last 252 sessions | 144 (57%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| QTTB | Biotechnology median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.59 | 0.49 |
| Macro sensitivityrate, dollar and credit exposure bucket | Low | Low 54% of 35 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Biotechnology names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| QTTB | |
|---|---|
| 1 week | −1.0% |
| 1 month | +10.6% |
| Year to date | +148.8% |
| 1 year | +249.0% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| QTTB | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 13 Jul |
| Average score0 most bearish, 100 most bullish | 69 |
| Bullish · bearisharticles above 60 · below 40 | 25 · 3 |
| Directionarticles whose tone is improving vs worsening | 25 ↑ 3 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 35 Biotechnology names Clavix covers; the tick is the sector median.
Growth
| QTTB | |
|---|---|
| Revenue growthyear over year | +155.8% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Biotechnology median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openQ32 Bio reported third-quarter 2026 results and presented SIGNAL-AA Part B data showing that responses to bempikibart at week 36 were maintained or deepened during a 16-week period without treatment. The company ended September with $289.6 million in cash and expects that balance to fund operations through the main results of a planned Phase 3 registration study.
Q32 Bio presented additional Part B data from the SIGNAL-AA trial showing that responses to bempikibart were maintained or deepened during a 16-week period off treatment in patients with alopecia areata, an autoimmune hair-loss condition. It plans regulatory discussions this quarter, a registration-directed trial in 1H 2027, and open-label extension data in 2H 2027; the provided excerpt contains no financial figures.
Several research firms have recently updated their ratings and price targets on Q32 Bio (QTTB). Leerink Partners began covering the stock with an "outperform" rating and a $40.00 price target on October 12, 2026, and Oppenheimer reaffirmed its "outperform" rating on October 1, 2026.
Leerink Partners initiated coverage of Q32 Bio (NASDAQ: QTTB) on Monday, assigning an "outperform" rating and a $40 price objective.
Q32 Bio shared additional Part B results from its Phase 2a trial of bempikibart in severe alopecia areata (an autoimmune condition causing patchy hair loss), reporting a 35.3% average reduction in scalp hair loss severity (SALT score) at Week 36, plus full maintenance of hair regrowth through 16 weeks off the drug. The company said the data support moving into a registration-directed program in the first half of 2027.
Nearest peers by size
Biotechnology| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| CELC | Celcuity Inc. | C+ | $3.39B | — | 0.19 | Compare |
| IOVA | Iovance Biotherapeutics Inc | D- | $3.94B | — | 0.84 | Compare |
| ERAS | Erasca, Inc. | C | $5.21B | — | 0.66 | Compare |
| PTCT | PTC Therapeutics, Inc. | B | $5.76B | 8.34 | 0.49 | Compare |
| CGON | CG Oncology, Inc. | B- | $6.00B | — | 0.32 | Compare |
| IONS | Ionis Pharmaceuticals, Inc. | B- | $6.67B | — | 0.36 | Compare |
| ARWR | Arrowhead Pharmaceuticals, Inc. | C+ | $8.71B | — | 1.39 | Compare |
| CYTK | Cytokinetics, Incorporated | B+ | $8.84B | — | 0.40 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.